featured
Efficacy of ABBV-383, a BCMA × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
J. Clin. Oncol 2022 Aug 27;[EPub Ahead of Print], A D'Souza, N Shah, C Rodriguez, PM Voorhees, K Weisel, OF Bueno, RK Pothacamury, KJ Freise, S Yue, JA Ross, AR Polepally, C Talati, S Lee, Z Jin, B Buelow, R Vij, S KumarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.